Ginkgo Bioworks Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue was $28M, while net loss and Adjusted EBITDA improved substantially YoY; FY cash burn guidance was reaffirmed at $125M–$150M. Autonomous-lab wins and Cloud Lab customer additions signal growing market adoption, though installations can take 6–12 months.
-
Q2 revenue fell 48% YoY, while H1 cash burn declined 3% to $93M; 2026 cash-burn guidance remains $125M–$150M. Nebula expansion, university lab awards, and ADME-One launch advance the autonomous-lab strategy.
-
Revenue and cash burn declined year-over-year as restructuring and the biosecurity spin-off took effect. The company is investing heavily in autonomous labs, with Nebula now exceeding 100 RACs and new partnerships expanding cloud-based lab services. Strong cash reserves support continued innovation.
Fiscal Year 2025
-
Restructuring and cost controls led to a 55% reduction in annual cash burn, with a strategic pivot to autonomous labs and divestiture of the biosecurity business. Major contract wins and AI collaborations highlight leadership in lab automation.
-
Q3 2025 saw a sharp reduction in cash burn and continued cost discipline, with revenue impacted by prior non-cash items and restructuring. The business is pivoting to AI-driven automation and tools, reaffirming 2025 revenue guidance and expanding key partnerships.
-
Cost reductions and improved profitability were achieved ahead of schedule, with strong cash reserves and a strategic shift toward automation, AI, and life science tools. Revenue guidance for 2025 was reaffirmed, while new product launches and market expansion are expected to drive future growth.
-
Achieved $205M in annualized cost reductions and improved adjusted EBITDA to -$47M in Q1 2025. Revenue guidance was raised to $167–$187M for 2025, with strong liquidity and new government contracts de-risking the outlook.
-
Biopharma partnerships are driving rapid growth, supported by operational streamlining and a strategic shift to direct sales of data, AI, and automation tools. New offerings like Datapoints and modular lab robotics are gaining traction with major biopharma and tech clients, positioning the company for a strong 2025.
Fiscal Year 2024
-
Cost reductions and restructuring led to a sharp drop in cash burn and improved adjusted EBITDA, with strong growth in Cell Engineering from large biopharma and government customers. New tools offerings are gaining traction, but 2025 guidance remains conservative due to market and government funding uncertainties.
-
Q3 saw accelerated cost reductions, improved adjusted EBITDA, and strong cash reserves, with updated 2024 revenue guidance reflecting a non-cash deferred revenue release. New customer wins and product launches in cell engineering and tools, plus expanded biosecurity offerings, position the company for future growth.
-
Cost reductions and a narrowed focus have positioned the business to support operations with customer fees, while new investments in modular robotics and data-as-a-service aim to democratize access to advanced biotech tools. The company is shifting toward a horizontal platform model, with multi-year contracts and a strong cash position supporting growth.
-
Revenue declined year-over-year, but active programs and new contracts grew, especially in cell engineering. Aggressive cost reductions and restructuring are on track, with new offerings like LDAS and biosecurity initiatives positioned for future growth. Guidance for 2024 was reaffirmed.